Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells $15,440.22 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) insider Douglas M. Hunt sold 4,374 shares of Puma Biotechnology stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $3.53, for a total transaction of $15,440.22. Following the completion of the transaction, the insider directly owned 168,337 shares of the company's stock, valued at $594,229.61. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Puma Biotechnology Trading Down 3.7%

Puma Biotechnology stock traded down $0.13 during trading hours on Friday, hitting $3.39. The company had a trading volume of 300,719 shares, compared to its average volume of 414,256. The firm has a market cap of $168.25 million, a P/E ratio of 4.40 and a beta of 1.29. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53. Puma Biotechnology, Inc. has a 1 year low of $2.23 and a 1 year high of $4.13. The company has a 50-day moving average price of $3.37 and a two-hundred day moving average price of $3.18.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd.

Institutional Investors Weigh In On Puma Biotechnology

Several large investors have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in shares of Puma Biotechnology by 3.8% in the 1st quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company's stock valued at $254,000 after purchasing an additional 3,117 shares in the last quarter. LPL Financial LLC raised its holdings in shares of Puma Biotechnology by 23.6% in the 4th quarter. LPL Financial LLC now owns 26,567 shares of the biopharmaceutical company's stock valued at $81,000 after purchasing an additional 5,080 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Puma Biotechnology by 42.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,083 shares of the biopharmaceutical company's stock valued at $59,000 after purchasing an additional 5,726 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of Puma Biotechnology by 5.8% during the 4th quarter. Prudential Financial Inc. now owns 106,285 shares of the biopharmaceutical company's stock worth $324,000 after acquiring an additional 5,800 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Puma Biotechnology by 36.5% during the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company's stock worth $70,000 after acquiring an additional 6,126 shares in the last quarter. Institutional investors own 61.29% of the company's stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.